Quillitin Pharma Pte. Ltd.
Quillitin Pharma is a Singapore-based specialty pharmaceutical company dedicated to the development and commercialization of products for the treatment of urological disorders. Our initial focus is to provide solutions addressing untreated erectile dysfunction (“ED”) in specific and large unmet market segments.
The diagnosis and treatment of certain urological conditions represents an expanding market with many poorly met medical needs that offer significant commercial potential for new pharmaceutical products and medical devices. Our first and lead product QPD101 meets this large unmet need in the male erectile dysfunction segment.
Information contained on this website is provided for business development and investor relations purposes only. Patients who suffer or believe they suffer from ED should contact their physician in the first instance.
About Erectile Dysfunction (ED)
As many as one in four adult males will experience ED with consequent impact on both patient and partner. The advent of phosphodiesterase inhibitors (PDEi), the first of which being Viagra (sildenafil), revolutionized treatment of this disorder. Since approval, in 1997 Viagra has been shown to be highly safe and generally effective. However, it has become equally obvious that PDEi can be less effective in situations where there is metabolic dysfunction (obesity and diabetes) and post certain surgical procedures, particularly radical prostatectomy.